You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBotulinum Toxin Type A
Accession NumberDB00083  (BIOD00092, BTD00092)
TypeBiotech
GroupsApproved, Investigational
Description

Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.

Protein structureDb00083
Protein chemical formulaC6760H10447N1743O2010S32
Protein average weight149322.7000
Sequences
>Botulinum Toxin Type A Sequence
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
Download FASTA Format
Synonyms
SynonymLanguageCode
BoNT/ANot AvailableNot Available
Bontoxilysin ANot AvailableNot Available
Botulinum neurotoxin type A precursorNot AvailableNot Available
BTX-ANot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Botoxinjection, powder, lyophilized, for solution100 [USP'U]intradermal; intramuscularAllergan, Inc.1989-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Botox Cosmeticinjection, powder, lyophilized, for solution50 [USP'U]intramuscularAllergan, Inc.2008-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Botoxinjection, powder, lyophilized, for solution200 [USP'U]intradermal; intramuscularAllergan, Inc.2010-01-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Botox Cosmeticinjection, powder, lyophilized, for solution100 [USP'U]intramuscularAllergan, Inc.2002-04-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Xeomininjection, powder, lyophilized, for solution50 [USP'U]intramuscularMerz Pharmaceuticals, LLC2010-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Xeomininjection, powder, lyophilized, for solution100 [USP'U]intramuscularMerz Pharmaceuticals, LLC2010-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dysportinjection, powder, lyophilized, for solution500 UintramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dysportinjection, powder, lyophilized, for solution300 UintramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Xeomininjection, powder, lyophilized, for solution100 [USP'U]intramuscularMerz Aesthetics. Inc2011-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Xeomininjection, powder, lyophilized, for solution50 [USP'U]intramuscularMerz Aesthetics. Inc2011-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dysportinjection, powder, lyophilized, for solution300 [USP&apos'U]intramuscularMedicis Pharmaceutical Corp2009-05-252015-03-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number93384-43-1
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
PharmacodynamicsA 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.
Mechanism of actionBotulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.
AbsorptionThe chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityBased on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintradermal; intramuscular100 [USP'U]
Injection, powder, lyophilized, for solutionintradermal; intramuscular200 [USP'U]
Injection, powder, lyophilized, for solutionintramuscular100 [USP'U]
Injection, powder, lyophilized, for solutionintramuscular300 U
Injection, powder, lyophilized, for solutionintramuscular300 [USP&apos'U]
Injection, powder, lyophilized, for solutionintramuscular50 [USP'U]
Injection, powder, lyophilized, for solutionintramuscular500 U
Prices
Unit descriptionCostUnit
Botox 200 unit vial1260.0USD vial
Dysport 500 unit vial852.0USD vial
Botox 100 unit655.2USD vial
Botox 100 unit vial630.0USD vial
Botox cosmetic 100 unit vial630.0USD vial
Botox cosmetic 50 unit vial346.8USD vial
Botox (100 - 200 unit/Vial)3.74USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada22805652005-11-152019-08-20
Canada23108452001-05-152014-06-07
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
hydrophobicity-0.368Not Available
isoelectric point6.06Not Available
References
Synthesis ReferenceNot Available
General Reference
  1. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. Pubmed
  2. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O’Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. Pubmed
  3. Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. Pubmed
  4. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. Pubmed
  5. Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. Pubmed
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (115 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AmikacinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
ArbekacinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
FramycetinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
GentamicinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
KanamycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
NeomycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
NetilmicinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
RibostamycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
SpectinomycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
StreptomycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
TobramycinMay enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.
Food InteractionsNot Available

Targets

1. Synaptosomal-associated protein 25

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Synaptosomal-associated protein 25 P60880 Details

References:

  1. Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. Pubmed
  2. Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. Pubmed
  3. Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis] Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. Pubmed
  4. Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. Pubmed
  5. Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Rho-related GTP-binding protein RhoB

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Rho-related GTP-binding protein RhoB P62745 Details

References:

  1. Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 03, 2014 14:26